The Invoiceable Section Is Where Sites Leave Money on the Table

THE BILLING GRID
A weekly column on research billing and coverage analysis, by Krishma Shah

The coverage analysis meeting has ended, the medical coverage analysis (MCA) is signed, and the site contract is moving through legal. Someone on the finance team opens the sponsor budget spreadsheet to start building the invoiceable section, compares the sponsor’s per-procedure rate to whatever number is in the cell, and accepts it. That is the moment most sites quietly leave money on the table.

It is not fraud risk that lives in the invoiceable section. It is underpricing. And unlike billing Medicare for sponsor-paid items, the fact pattern at the center of the Rush University Medical Center clinical-trial billing settlement, which became the standard teaching example in research billing compliance, underpricing is invisible. No audit flags it. No monitor questions it. The site simply recovers less than it is entitled to recover, and no one ever notices.

What the Invoiceable Section Actually Is

A coverage analysis assigns every protocol-required procedure at every visit a designation. Items designated SOC (standard of care) are billable to Medicare or the patient’s insurer when the trial meets the qualifying criteria under NCD 310.1, which governs routine costs in qualifying clinical trials. Items designated RES (research costs) are the sponsor’s financial obligation. Items designated NB or INV (non-billable or invoiceable) are tracked separately because they either have no billable home or they are research-paid items that need to be priced and invoiced back to the sponsor.

The invoiceable section of the budget is where the INV-designated items land. It is the reconciliation point between what the MCA says the sponsor owes and what the site actually charges for those procedures. The MCA is a coverage document. The budget is a pricing document. They should talk to each other. At most sites, they do not.

The MAX Rule and Why Sites Miss It

The operating principle for pricing research-paid items is straightforward: bill the greater of the sponsor’s offered rate or the site’s charge master rate for that procedure. Call it the MAX rule. If the sponsor offers $85 for a procedure that carries a charge master rate of $140, the site should invoice $140 and negotiate from there, or at minimum flag the gap before executing the budget. If the sponsor offers $200 for a procedure the charge master prices at $95, the sponsor rate wins.

The MAX rule is not complicated. What is complicated is applying it at the procedure level across an entire visit grid, for every INV-designated item, using charge master data that is often siloed in a different department from the people building the research budget. The finance team building the budget may not have ready access to current charge master rates. The charge master team may not know a research budget is being negotiated. The MCA author may have finished the coverage document weeks before the budget conversation started. The result is a budget built against the sponsor’s numbers, unreconciled against the charge master, and signed before anyone has done the comparison.

A Worked Example: The Imaging Line Item

Take a protocol that requires contrast-enhanced CT scans every eight weeks for nine cycles. In the MCA, the correct designation is nine research-paid visits, each with a CT scan and contrast administration. The budget invoiceable section should carry nine line items, each priced at the MAX of the sponsor CT rate versus the charge master CT rate.

Here is where two separate errors compound each other. First, if the MCA was built from a template that decomposed the scan set into components rather than reading the parent schedule, the MCA may designate one visit rather than nine. That error flows directly into the budget: the invoiceable section carries one CT line item, the site invoices once, and eight cycles of imaging revenue disappear. This is the imaging frequency error that templates produce and human reviewers catch, but only if someone is looking at the protocol schedule alongside the MCA rather than trusting the output.

Second, even if the nine visits are correctly counted, the CT line may be priced at the sponsor’s offered rate without a charge master comparison. In a real budget negotiation, a contrast CT with interpretation can carry a charge master rate that is meaningfully higher than a sponsor’s standard budget offering, particularly at academic medical centers where charge master rates reflect facility overhead, radiologist professional fees, and PACS infrastructure. Sites I work with have found gaps of 30 to 50 percent between sponsor-offered imaging rates and charge master rates on the same procedure. Across nine cycles, that gap compounds into a material budget shortfall that the site will absorb silently for the life of the trial.

The Lab Citation Problem

The same logic applies to laboratory procedures, with an additional compliance layer. When a CBC is designated as a research-paid item in the MCA, the coverage citation matters: a CBC maps to NCD 190.15, and writing “routine labs” with no citation is the documentation weak point that an auditor will question. But the pricing problem is separate from the citation problem. Even a correctly cited, correctly designated lab procedure can be underpriced in the invoiceable section if no one has compared the sponsor’s per-panel rate to the charge master rate for the specific CPT codes involved.

The defensible unit in a coverage analysis is the visit-grid cell: the same procedure can be SOC at one visit and RES at another, depending on the protocol schedule and the clinical context. That cell-level granularity in the MCA has to carry through to the invoiceable section at the same resolution. A lump “lab panel” line item in the budget that bundles multiple CPTs at a single sponsor-offered rate is almost certainly underpriced relative to what an itemized charge master comparison would show.

Where This Lives on the Critical Path

The MCA sits on the site-activation critical path alongside the contract and IRB submission. Sites that treat the invoiceable section as a contract negotiation afterthought are compressing the only window they have to correct pricing before the budget is executed. Once the contract is signed and the study is open, reopening budget line items requires a budget amendment, sponsor agreement, and often a contract amendment. The friction cost of fixing underpricing mid-trial is high enough that most sites absorb the loss instead.

The correction is procedural, not technical. Before the budget is executed, someone with charge master access needs to pull current rates for every INV-designated procedure in the MCA, compare them line by line to the sponsor’s offered rates, and flag every cell where the charge master rate exceeds the sponsor rate. That comparison is the invoiceable reconciliation. It takes time that startup timelines rarely budget for. But the alternative is signing a contract that underpays the site for every research-paid procedure in the protocol, for every patient, for the entire trial duration. The math on that is never favorable.